Drug Fix: Wegovy’s CV Benefits, Mifepristone And Water Contamination, US FDA Back To The Office?
Citeline Podcasts
English - August 11, 2023 18:37 - 33 minutes - 19.9 MB - ★★★★★ - 24 ratingsBusiness News Business News Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Pink Sheet reporters and editors discuss the impact of a study showing cardiovascular benefits for the weight loss drug Wegovy (:45), another attempt to restrict mifepristone access (16:15), and a new threat to the US FDA’s hybrid work policy (26:35).
More On These Topics From The Pink Sheet
Wegovy’s Cardiovascular Benefits May Improve, But Not Transform, Insurance Coverage In Obesity:
https://pink.pharmaintelligence.informa.com/PS148672/Wegovys-Cardiovascular-Benefits-May-Improve-But-Not-Transform-Insurance-Coverage-In-Obesity
Obesity Advocates Meet With FDA Commissioner, Push On Difference vs. Short-Term Weight-Loss:
https://pink.pharmaintelligence.informa.com/PS148673/Obesity-Advocates-Meet-With-FDA-Commissioner-Push-On-Difference-vs-ShortTerm-WeightLoss
New Attack Against FDA’s Mifepristone Approval Targets Potential Water Contamination:
https://pink.pharmaintelligence.informa.com/PS148671/New-Attack-Against-FDAs-Mifepristone-Approval-Targets-Potential-Water-Contamination
Peter Marks’ Fears May Come True: White House Wants More In-Person Work:
https://pink.pharmaintelligence.informa.com/PS148674/Peter-Marks-Fears-May-Come-True-White-House-Wants-More-In-Person-Work